Long noncoding RNAs in atherosclerosis and vascular injury: pathobiology, biomarkers, and targets for therapy

JB Pierce, MW Feinberg - Arteriosclerosis, thrombosis, and …, 2020 - Am Heart Assoc
JB Pierce, MW Feinberg
Arteriosclerosis, thrombosis, and vascular biology, 2020Am Heart Assoc
Despite major advances in the primary and secondary prevention of atherosclerosis and its
risk factors, atherosclerotic cardiovascular disease remains a major clinical and financial
burden on individuals and health systems worldwide. In addition, neointima formation and
proliferation due to mechanical trauma to the vessel wall during percutaneous coronary
interventions can lead to vascular restenosis and limit the longevity and effectiveness of
coronary revascularization. Long noncoding RNAs (lncRNAs) have emerged as a novel …
Despite major advances in the primary and secondary prevention of atherosclerosis and its risk factors, atherosclerotic cardiovascular disease remains a major clinical and financial burden on individuals and health systems worldwide. In addition, neointima formation and proliferation due to mechanical trauma to the vessel wall during percutaneous coronary interventions can lead to vascular restenosis and limit the longevity and effectiveness of coronary revascularization. Long noncoding RNAs (lncRNAs) have emerged as a novel class of epigenetic regulators with critical roles in the pathogenesis of atherosclerosis and restenosis following vascular injury. Here, we provide an in-depth review of lncRNAs that regulate the development of atherosclerosis or contribute to the pathogenesis of restenosis following mechanical vascular injury. We describe the diverse array of intracellular mechanisms by which lncRNAs exert their regulatory effects. We highlight the utility and challenges of lncRNAs as biomarkers. Finally, we discuss the immense translational potential of lncRNAs and strategies for targeting them therapeutically using oligonucleotide-based therapeutics and novel gene therapy platforms.
Am Heart Assoc